Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Coco S, Truini A, Alama A, Dal Bello MG, Venè R, Garuti A, Carminati E, Rijavec E, Genova C, Barletta G, Sini C, Ballestrero A, Boccardo F, Grossi F. Coco S, et al. Among authors: rijavec e. Target Oncol. 2015 Sep;10(3):393-404. doi: 10.1007/s11523-014-0344-7. Epub 2014 Oct 25. Target Oncol. 2015. PMID: 25341405
Immune checkpoint inhibitor therapy for hepatocellular carcinoma.
Ramai D, Shapiro A, Facciorusso A, Bareggi C, Gambini D, Rijavec E, Tomasello G, Galassi B, Ghidini M. Ramai D, et al. Among authors: rijavec e. Ann Gastroenterol. 2022 Nov-Dec;35(6):568-576. doi: 10.20524/aog.2022.0746. Epub 2022 Oct 3. Ann Gastroenterol. 2022. PMID: 36406972 Free PMC article. Review.
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.
Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP. Salvi S, et al. Among authors: rijavec e. Cancer Immunol Immunother. 2012 Sep;61(9):1463-72. doi: 10.1007/s00262-012-1211-y. Epub 2012 Feb 9. Cancer Immunol Immunother. 2012. PMID: 22318401 Free PMC article.
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Grossi F, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P. Grossi F, et al. Among authors: rijavec e. Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12. doi: 10.1007/s00280-012-1848-4. Epub 2012 Feb 21. Cancer Chemother Pharmacol. 2012. PMID: 22349923 Clinical Trial.
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.
Genova C, Rijavec E, Barletta G, Sini C, Dal Bello MG, Truini M, Murolo C, Pronzato P, Grossi F. Genova C, et al. Among authors: rijavec e. Expert Opin Biol Ther. 2012 Jul;12(7):939-48. doi: 10.1517/14712598.2012.681371. Epub 2012 Apr 16. Expert Opin Biol Ther. 2012. PMID: 22506716 Review.
Pemetrexed for the treatment of non-small cell lung cancer.
Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, Grossi F. Genova C, et al. Among authors: rijavec e. Expert Opin Pharmacother. 2013 Aug;14(11):1545-58. doi: 10.1517/14656566.2013.802774. Epub 2013 May 17. Expert Opin Pharmacother. 2013. PMID: 23683110 Review.
Role of microRNAs in malignant mesothelioma.
Truini A, Coco S, Alama A, Genova C, Sini C, Dal Bello MG, Barletta G, Rijavec E, Burrafato G, Boccardo F, Grossi F. Truini A, et al. Among authors: rijavec e. Cell Mol Life Sci. 2014 Aug;71(15):2865-78. doi: 10.1007/s00018-014-1584-5. Epub 2014 Feb 23. Cell Mol Life Sci. 2014. PMID: 24562347 Free PMC article. Review.
109 results